Lung Microbiome in Cystic Fibrosis.
CFTR
cystic fibrosis
lung
microbiome
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
27 Jan 2021
27 Jan 2021
Historique:
received:
28
12
2020
revised:
21
01
2021
accepted:
22
01
2021
entrez:
30
1
2021
pubmed:
31
1
2021
medline:
31
1
2021
Statut:
epublish
Résumé
The defective mucociliary clearance due to CFTR malfunctioning causes predisposition to the colonization of pathogens responsible for the recurrent inflammation and rapid deterioration of lung function in patients with cystic fibrosis (CF). This has also a profound effect on the lung microbiome composition, causing a progressive reduction in its diversity, which has become a common characteristic of patients affected by CF. Although we know that the lung microbiome plays an essential role in maintaining lung physiology, our comprehension of how the microbial components interact with each other and the lung, as well as how these interactions change during the disease's course, is still at an early stage. Many challenges exist and many questions still to be answered, but there is no doubt that manipulation of the lung microbiome could help to develop better therapies for people affected by CF.
Identifiants
pubmed: 33513903
pii: life11020094
doi: 10.3390/life11020094
pmc: PMC7911450
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Eur J Clin Nutr. 2017 Nov;71(11):1336-1340
pubmed: 28901331
Thorax. 2020 Sep;75(9):780-790
pubmed: 32631930
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5809-14
pubmed: 22451929
Thorax. 2019 Aug;74(8):740-748
pubmed: 31203197
mSystems. 2020 Jun 23;5(3):
pubmed: 32576651
PLoS One. 2016 Oct 14;11(10):e0164510
pubmed: 27741283
Respir Res. 2019 Dec 3;20(1):272
pubmed: 31796027
Am J Rhinol Allergy. 2019 Mar;33(2):129-136
pubmed: 30585080
J Pediatr Pharmacol Ther. 2020;25(3):192-197
pubmed: 32265602
Chest. 2021 Jan;159(1):93-102
pubmed: 32966813
J Gen Physiol. 2002 Sep;120(3):407-18
pubmed: 12198094
Ann Am Thorac Soc. 2013 Jun;10(3):179-87
pubmed: 23802813
Int J Chron Obstruct Pulmon Dis. 2016 Sep 30;11:2419-2426
pubmed: 27757027
Sci Rep. 2015 May 14;5:10241
pubmed: 25974282
Front Physiol. 2018 Aug 21;9:1168
pubmed: 30246806
Genes (Basel). 2020 May 11;11(5):
pubmed: 32403302
Nat Rev Immunol. 2016 May 27;16(6):341-52
pubmed: 27231050
PLoS One. 2012;7(9):e45001
pubmed: 23049765
Heliyon. 2018 Sep 17;4(9):e00795
pubmed: 30238064
Nat Med. 2014 Jun;20(6):642-7
pubmed: 24813249
Hum Mutat. 2019 Jun;40(6):742-748
pubmed: 30851139
PLoS One. 2013 Dec 17;8(12):e82432
pubmed: 24358183
J Med Case Rep. 2017 Oct 1;11(1):278
pubmed: 28964265
Int J Antimicrob Agents. 2017 Sep;50(3):427-435
pubmed: 28666755
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6003-12
pubmed: 27458217
Sci Rep. 2020 Apr 2;10(1):5806
pubmed: 32242045
J Cyst Fibros. 2014 Sep;13(5):515-9
pubmed: 24618508
Clin Med (Lond). 2017 Dec;17(6):525-529
pubmed: 29196353
Eur Respir J. 2017 Mar 29;49(3):
pubmed: 28356374
Respirology. 2020 Mar;25(3):244-245
pubmed: 31868282
BMC Pulm Med. 2018 Dec 22;18(1):196
pubmed: 30577776
Am J Respir Crit Care Med. 2017 Jun 15;195(12):1617-1628
pubmed: 28222269
Eur Respir J. 2017 Nov 16;50(5):
pubmed: 29146601
PLoS One. 2016 Mar 04;11(3):e0149998
pubmed: 26943329
PLoS One. 2017 Mar 16;12(3):e0173741
pubmed: 28301571
Science. 2016 Mar 18;351(6279):1296-302
pubmed: 26989247
Microbiome. 2013 Nov 01;1(1):27
pubmed: 24451123
Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8
pubmed: 19729669
Curr Med Chem. 2016;23(24):2736-2745
pubmed: 27356533
J Clin Invest. 2002 Mar;109(5):571-7
pubmed: 11877463
Front Microbiol. 2020 Feb 25;11:301
pubmed: 32158441
Environ Microbiol. 2010 May;12(5):1293-303
pubmed: 20192960
Front Microbiol. 2018 Sep 19;9:2147
pubmed: 30283410
Pharmacol Res. 2020 Dec;162:105267
pubmed: 33127556
Cell Rep. 2018 Sep 25;24(13):3528-3538
pubmed: 30257213
Immunity. 2020 Feb 18;52(2):241-255
pubmed: 32075727
Clin Infect Dis. 2015 Mar 1;60(5):703-12
pubmed: 25425629